A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

In all, researchers found that people taking GLP-1 medications had lower risks for 42 health outcomes, including liver ...

The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an ...

The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...

Novo Nordisk ( NYSE:NVO) and Eli Lilly ( NYSE:LLY) are making headlines againthis time, for potential benefits beyond weight ...

GLP-1 class of weight loss and diabetes drugs are linked to previously unrecognized health risks and benefits, according to a ...

A comprehensive new study supports evidence of the myriad health benefits of GLP-1 medications like Ozempic and Mounjaro — ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...

From Alzheimer's prevention to weight-loss dominance, Novo bets on innovation and share repurchases amid Medicare pressure.

Glucagon-like peptide-1 receptor agonist use corresponded with risk reductions for dozens of diseases and adverse health ...

A discovery reveals that weight loss drugs like Ozempic and Mounjaro can positively impact 175 diseases and conditions beyond ...

SAN FRANCISCO, CA / ACCESS Newswire / January 21, 2025 / Gala introduces a groundbreaking digital health platform that ...